Filspari denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for filspari are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Flags Filspari as Duplicate Therapy — and Why That May Be Wrong

Filspari (sparsentan) is an FDA-approved treatment for IgA nephropathy (IgAN). Aetna's duplicate-therapy denial means the plan's system identified another active claim — often a renin-angiotensin-aldosterone system (RAAS) inhibitor — and flagged sparsentan as duplicating it. This logic misunderstands Filspari's mechanism: sparsentan is a dual-acting endothelin and angiotensin receptor antagonist with a distinct FDA-approved indication, not a therapeutic duplicate of a standard RAAS inhibitor.

This type of denial is well-suited to appeal because the clinical distinction is clear and the FDA approval itself provides strong documentary evidence.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, submit your internal appeal within the deadline shown on your denial notice (commonly 180 days).
• External review: If the internal appeal is denied, an independent external reviewer can evaluate whether the denial is consistent with generally accepted medical standards. The external-review window is typically approximately four months from the original denial.
• Expedited review: If your kidney function is declining rapidly, request expedited review.

## Documentation to Gather

1. Diagnosis confirmation — biopsy-confirmed IgA nephropathy diagnosis date and current clinical status (proteinuria trend, kidney function trajectory per chart). 2. Current medication list — complete list of active prescriptions so the appeal can directly address why each existing agent does not duplicate Filspari's mechanism or indication. 3. Prescriber medical-necessity letter — your nephrologist should explain sparsentan's distinct dual mechanism (endothelin-A and AT1 receptor antagonism) relative to other agents, and why combination or substitution is not clinically equivalent. 4. FDA label reference — attach the FDA-approved prescribing information for Filspari confirming the specific indication and mechanism, demonstrating it is not a formulary duplicate.

## Criteria-Mapping Structure

Obtain Aetna's published clinical policy for Filspari/sparsentan. Build a response grid:

| Aetna Requirement | Your Evidence | |---|---| | Biopsy-confirmed IgAN diagnosis | [Date of biopsy/pathology report] | | Distinct mechanism from current agents | [FDA label page + prescriber letter] | | No true therapeutic duplicate exists | [Prescriber explanation + medication list] | | Ongoing proteinuria/progression | [Lab trend dates from chart] |

Address each line of the duplicate-therapy criterion directly. Emphasize that the FDA specifically approved sparsentan as a distinct therapeutic agent for IgAN, not as a reformulation of any existing drug class.